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OBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing
countries are underreported, even though the similar classic regimens are widely used.
METHODS: We conducted a retrospective comparison of ‘‘MEC’’ (mitoxantrone, etoposide, and cytarabine) and
‘‘FLAG-IDA’’ (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML.
RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA.
A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) died before
undergoing bone marrow assessment. No statiscally significant difference in CR rate was found between the
two protocols (p=0.447). The median survival in the total cohort was 4 months, with a 3-year overall survival (OS)
rate of 9.7%. In a multivariable model including age, fms-like tyrosine kinase 3 (FLT3) status, and stem-cell
transplantation (SCT), only the last two indicators remained significant: FLT3-ITD mutation (hazard ratio [HR]
=4.6, po0.001) and SCT (HR=0.43, p=0.01).
CONCLUSION: In our analysis, there were no significant differences between the chosen regimens. High rates of
early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are
eligible for intensive salvage therapy in this setting. The FLT3-ITDmutation and SCT remained significant factors
for survival in our study, in line with the results of previous studies.
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’ INTRODUCTION
Acute myeloid leukemia (AML) is a highly heterogeneous
disease in adults that is fatal in the majority of patients (1). It is
estimated that only 15%–40% of patients achieve long-term
survival with current approaches, which include genetic risk
stratification and allogeneic stem-cell transplantation (SCT) for
intermediate-high risk subjects (2,3). Although toxicity is a
major concern when treating AML in adults, the high refract-
oriness and rate of relapse seems to be the leading cause of
death, even in developing countries (4,5).
There is no consensus regarding the best salvage regimen
for refractory or relapsed AML (r/rAML); the regimen is tradi-
tionally based on high-dose cytarabine in a changeable combi-
nation with anthracyclines, purine analogs, and etoposide (6,7).
The recent incorporation of innovative drugs such as gemtu-
zumab, ozogamicin, hypomethylating agents, and fms-like tyro-
sine kinase 3 receptor (FLT3)-inhibitors has improved outcomes
in this setting, but these approaches are not widely available
(8-10). Furthermore, the reported complete response (CR) rates
vary from 15% to 65% following the SCT procedure, which is
reported to be an essential step toward achieving long-term
remission (6).
The outcomes of r/rAML patients in developing countries
are underreported, even though the similar regimens are
widely used. We conducted a single center retrospective
comparison of two regimens, ‘‘MEC’’ (mitoxantrone, etopo-
side, and cytarabine) and ‘‘FLAG-IDA’’ (fludarabine, cytar-
abine, idarubicin, and filgrastim), in the adult population
with refractory or first relapse of AML, with the aim to
describe this population and their outcomes.
’ MATERIALS AND METHODS
Study design and ethics statement
This was a retrospective single-center study conducted at
the Institute of Cancer of São Paulo (ICESP), University of
São Paulo (USP), in Brazil. Clinical and laboratory data were
obtained from the databases of the Leukemia Clinic of
Discipline of Hematology. All procedures were in accordanceDOI: 10.6061/clinics/2020/e1566
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with the ethical standards of the institutional research com-
mittee (CAPPEsq – CAAE: 80673316.3.0000.0068) and with
the 1964 Helsinki Declaration and its later amendments, or
comparable ethical standards.
Patients
All patients aged above 16 years who received MEC or
FLAG-IDA between December 2009 and January 2019 were
initially included. Patients who received one of the above
regimens as first-line therapy or patients with other diagno-
ses besides non-promyelocytic AML were excluded. Patients
who did not receive the salvage regimen at our center were
also excluded from this study.
The AML diagnosis was established based on the World
Health Organization criteria, using morphology, immu-
nophenotyping, and conventional karyotyping in all cases.
Screening for NPM1 and FLT3 mutations was performed in
all cases by standardized methods (11). CEBPA mutations
and BCR-ABL1 fusion were heterogeneously screened. Some
cases had their genetic evaluation complemented by FISH if
necessary. Clinical variables were retrospectively collected
and managed using REDCap electronic data capture tools
hosted at the University of São Paulo (12).
Definitions, treatments, and response evaluation
In our center, the local protocol recommended a ‘‘7+3’’ clas-
sical regimen for first-line remission induction in fit patients
with AML, which involves daunorubicin, idarubicin, or mito-
xantrone as the anthracycline/anthracenedione (13). Response
is assessed 7–14 days after the end of induction, as classically
recommended (14). Patients who did not achieve partial remis-
sion (50% reduction in bone marrow [BM] blasts, resulting in
less than 25% blasts), CR (absence of extramedullary leukemia,
o5% blasts in the BM, absence of circulating blasts or blasts
with Auer rods, and platelet count X100 109/L and neu-
trophil count X1.0 109/L), or CRi (same criteria for CR,
except that incomplete recovery of blood count was allowed)
were considered refractory to the first-line regimen (13,14).
Patients who achieved partial remission after one cycle recei-
ved a second ‘‘7+3’’ cycle at the discretion of the physician
(13). Relapse was defined as the reappearance of blasts post-
CR in the peripheral blood or BM or as extramedullary dis-
ease post-CR (14). Only patients with refractory or relapsed
disease following standard upfront therapy were included in
this analysis and were classified into the following groups:
refractory, early relapsed (relapse within 1 year from the first
CR), and late relapsed (relapse after 1 year of remission).
Only the first salvage regimen was considered in this study.
Presumably, all patients were referred to undergo SCT as con-
solidation therapy after the salvage regimen at the discretion
of the physician.
Patients were grouped according to their cytogenetic risk
as it follows: (1) favorable: presence of RUNX1-RUNX1T1 or
CBFB-MYH11 gene fusions or an isolated NPM1 mutation;
and (2) unfavorable: presence of an isolated FLT3 mutation,
cytogenetic abnormalities involving chromosomes 5 or 7,
lysine methyltransferase 2A (KMT2A) rearrangement, com-
plex karyotype (X3 chromosomal abnormalities excluding
those with favorable-risk fusions), BCR-ABL1 fusion on real
time-polymerase chain reaction (RT-PCR) or conventional
karyotype, or AML cases secondary to therapy or secondary
to previously known myeloid neoplasm. The remaining
cases were categorized to have intermediate genetic risk.
Historically, our institution has recommended MEC as a
standard therapy for r/rAML. Over the past several years,
FLAG-IDA became an option for some physicians based on
personal experience and the fluctuating availability of some
drugs in our country. Salvage regimens were administered as
previously reported: (1) MEC - mitoxantrone 6 mg/m2/day
IV on days 1–6, etoposide 80 mg/m2/day IV on days 1–6,
and cytarabine 1 g/m2/day IV on days 1–6 (15); (2) FLAG-
IDA - 30 mg/m2/day fludarabine on days 1–5, 2 g/m2/day
cytarabine on days 1–5, and 300 mcg/day of filgrastim on
days 0–5 (16). Patients with Philadelphia-positive de novo
AML were allowed to receive a tyrosine-kinase inhibitor
along with the salvage regimen if indicated.
Bacterial colonization was determined weekly in all
patients by rectal or perineal swabs during the induction
phase and defined as isolation of any bacteria in the absence
of clinical findings of infection. Invasive fungal infection
(IFI) was defined as any clinical evidence of fungal disease,
such as a suggestive lung nodule or necrotizing sinusitis, or
fungus isolation in the blood or bronchoalveolar lavage.
Serum galactomannan was also used as an ancillary test for
this diagnosis. Febrile neutropenia and other complications
were managed at the discretion of the physician or managed
using filgrastim during BM aplasia according to local protocols.
Statistical Analysis
Categorical variables were summarized as frequencies and
percentages, and continuous variables were summarized as
median and range. Pairwise comparisons between patient
subgroups were performed by the Mann-Whitney test for
continuous variables and by Pearson’s chi-square or Fisher’s
exact test for categorical variables. Event-free survival (EFS)
was calculated from the time of treatment initiation until the
date of no response, relapse, or death. Overall survival (OS)
was calculated from the time of treatment initiation until
death. Survival curves were plotted with the Kaplan-Meier
method and compared using the log-rank test. The median
follow-up time was estimated by reversing the codes for the
censoring indicator in the Kaplan-Meier analysis. The cumu-
lative incidence of relapse (CIR) was calculated considering
death as a competitor and compared by Grey’s test (17). In an
attempt to equalize both groups according to baseline
characteristics, logistic regression was used for propensity
score calculation, including for age, indication for salvage
treatment, and FLT3 status. Propensity score analysis with
1:1 matching was performed with the nearest neighbor
matching method using calipers of width equal to 0.25 of the
standard deviation of the logit of the propensity score to
balance the baseline differences between cohorts. Factors
associated with CR were investigated by logistic regression,
and factors associated with survival endpoints were inves-
tigated by Cox regression. All analyses were performed using
Statistical Software for Social Sciences version 22.0 (SPSS,
Chicago, IL) and R software package version v 3.5.1 (R Foun-
dation for Statistical Computing; www.r-project.org). A two-
sided p-value o0.05 was considered statistically significant.
’ RESULTS
Patients
In our database, we identified 70 AML patients who
received MEC or FLAG-IDA from 2009 to 2019. Four patients
were excluded due to misdiagnosis (three had blastic phase
chronic myeloid leukemia and one had acute lymphoblastic
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leukemia), four received FLAG-IDA as a first-line therapy for
AML instead of ‘‘7+3’’, and two were excluded because they
had received a hypomethylating agent as first-line therapy
for AML. Therefore, 60 patients were included in the final
analysis.
Most patients were female (52%) with a median age of
45 years (range, 17–69). There were no cases of therapy-related
AML in this cohort. Four AML cases (7%) were secondary
to myeloproliferative neoplasm (MPN) or myelodysplastic
syndrome (MDS). A white blood cell (WBC) count above
30 109/L was present at diagnosis in 45% of cases. Regard-
ing the genetic characterization, the karyotype was abnormal
in 50% of cases. Core-binding factor alterations, namely
RUNX1-RUNX1T1 and CBFB-MYH11 fusions, were found in
5% and 3% of subjects, respectively. In total, 22% of patients
had an NPM1 mutation, with an associated FLT3 internal
tandem duplication (ITD) present in the majority (7/13
NPM1-mutated cases). All FLT3-ITD positive cases had an
accompanying NPM1 mutation. Two cases of Philadelphia-
positive de novo AML were also found. Two patients had
chronic human immunodeficiency virus infection and also
received antiretroviral therapy. The baseline characteristics of
the whole cohort are summarized in Table 1.
Previous treatments and salvage regimens
All patients received a standard upfront regimen (‘‘7+3’’),
including daunorubicin (89%), idarubicin (8%), or mitoxan-
trone (3%). Three patients underwent SCT in the first CR and
were post-SCT relapses. Among the included patients, 43%
received the salvage regimen due to refractoriness to the
first-line therapy. The remaining subjects were early or late-
relapsed (45% and 12%, respectively).
In total, 28 patients received MEC and 32 received FLAG-
IDA in this cohort. The two subjects with Philadelphia-
positive de novo AML in the MEC arm received dasatinib
concomitantly. By comparing the baseline characteristics of
both groups, no significant differences were found in age,
sex, initial WBC count, bacterial colonization, genetic risk,
and FLT3 status. When it comes to the indication for salvage
treatment, there were more refractory cases in FLAG-IDA
group (56% vs. 28%, p=0.029) (Table 2).
Responses and survival data
Considering the whole cohort, 17/60 achieved CR and
12/60 achieved CRi, with a total CR rate (CR+CRi) of 48.3%
(95% confidence interval [CI], 35.4–61.5). In total, 16 patients
(27%) died after the beginning of the salvage regimen, which
precluded a BM assessment to determine response; there
were no statistically significant differences between these
patients and the rest of the cohort regarding age, indication
for treatment, genetic risk, and colonization data. All patients
had febrile neutropenia, with admission to the intensive care
unit (ICU) in 47% of cases.
By univariate analysis, only age affected the CR rate (p=0.045).
No significant difference in CR rate was found between the two
protocols (MEC 53.5 vs. FLAG-IDA 43.7%, p=0.447). Further-
more, there were more refractory patients in the FLAG-IDA arm
(37.5% vs. 4%, p=0.02), but more patients died early in the MEC
arm (35.7% vs. 18.7%, p=0.137), even though the latter was not
statistically significant. After correcting the initial differences
between the two groups regarding indication for salvage
through a propensity score calculation (Appendix), a post-
matching cohort with 44 subjects was found. In this cohort, no
difference in the refractoriness rate could be detected (p=0.077).
In the whole cohort, 17 patients proceeded to allogeneic
SCT, 15 in CR/CRi and 2 with active disease, with no
significant difference in the SCT execution rate between the
two groups (p=0.470). Only 4/17 transplanted patients were
alive by the time of this evaluation. In total, 25% of patients
received a second salvage regimen after relapse or refractori-
ness, and a minority received 3 or 4 different salvage
regimens for refractory disease. In the total cohort, 12% of
patients died in remission from infection, and IFI was
documented in 12% of subjects.
The median follow-up was 48 months (range, 0–85). The
median survival in the total cohort was 4 months (95% CI,
2.7–9.2), with a 3-year OS rate of 9.7% (95% CI, 4–23.7) and a
3-year EFS rate of 7.5% (95% CI, 2.5–22.4) (Figure 1). In the
univariate analysis, age (p=0.02), FLT3 status (po0.001), and
SCT procedure (p=0.002) were significantly associated with
OS. The chosen regimen did not influence OS or EFS in our
analysis and had no influence on the genetic risk, coloniza-
tion, or time of relapse (Figure 2). The 3-year CIR in patients
who responded to the salvage regimen was 30.8% (95% CI,
18–45), with age being the only significantly associated factor
(p=0.019).
In a multivariable model for EFS that included age, FLT3
status, and SCT procedure, only the last two indicators
remained significant: FLT3-ITD mutation (hazard ratio [HR]
=4.6 [95% CI, 1.9–11.4], po0.001) and SCT procedure
(HR=0.43 [95% CI, 0.22–0.82], p=0.01).
Table 1 - Baseline characteristics of the total cohort (n=60).
Age (median, range, IQR) 45.5 (17–69, 33.7–54)
Sex Female (51.7%)
WBC (109/L) (median, range, IQR) 17.4 (0.58–409.4, 3.3–61.2)
Conventional karyotype Diploid - 43.3%
Abnormal - 50%
No metaphasis - 6.7%
Secondary to MDS or MPN 6.7%
Classification (%) NOS - 47%
NPM1 mut - 22%
RUNX1-RUNX1T1 - 5%
CBFB-MYH11 - 3%
KMT2A rearrangement - 3%
5 or 7 abnormalities - 10%
Complex karyotype (X3
chromosomal abnormalities) -
7%
Philadelphia de novo - 3%
Genetic risk Favorable - 18.3%
Intermediate - 51.6%
High - 30.1%
FLT3 status (%) (missing=3.5%) Wild - 77.2%
ITD - 12.3% (25)
TKD - 10.5% (5)
CNS disease (%) (missing=17, 28.3%) Positive - 3 cases (7%)
Previous induction Daunorubicin 60 mg/m2 -
66.7%
Daunorubicin 90 mg/m2 -
21.7%
Idarubicin 12 mg/m2 - 8.4%
Mitoxantrone - 3.3%
Indication for salvage treatment Refractory - 43.3%
Early relapsed (o1 y) - 45%
Late relapsed (X1 y) - 11.7%
Previous SCT 3 pts
HIV infection 2 pts
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’ DISCUSSION
In this manuscript, we reviewed the medical charts of
60 patients with r/rAML treated with two standard regimens,
MEC and FLAG-IDA, at our center. As expected, a grea-
ter proportion of patients with intermediate-high risk disease
at diagnosis was included, especially those with a high pro-
portion of NPM1 plus FLT3-ITD mutations. Admittedly, few
patients with the FLT3-ITD mutation achieve long-term sur-
vival even when allogeneic SCT is performed after the first CR,
therefore enriching the r/rAML population in this AML
subset. This is especially true in centers where FLT3 inhibi-
tors are not yet available (18).
In our study, patients who did not achieve CR at the end of
the induction phase or at a least partial response in the early
BM assessment were considered refractory and accordingly
received a salvage regimen. Currently, in an attempt to
standardize further studies addressing this question, recom-
mendations from the European Leukemia Net (ELN) (19)
expert panel have defined refractory AML as failure to
achieve CR following exposure to at least two courses of
intensive induction therapy. In this guide, it was also
suggested that the second intensive regimen should ideally
include high-dose cytarabine, which is in line with the most
recent National Comprehensive Cancer Network (NCCN)
guidelines (19,20). Although a significant proportion of
patients achieve a CR after a second course of chemotherapy,
it is not clear whether those patients have the same prognosis
as those who received only one course of chemotherapy (6).
Ferguson et al. (21) examined this issue in a retrospective
analysis of 8907 patients included in UK Medical Research
Council (MRC) trials and found that patients who achieved
CR after one course of chemotherapy did considerably better
than those who required a second cycle (5-year OS 40 versus
8%–21%, po0.0001). Furthermore, a survival difference was
also noted between those with PR and truly refractory
patients (po0.0001). Achievement of PR was recently rei-
terated as a significant prognostic factor by Fleming et al. (22)
in an Australian cohort. Although it is a debatable definition
in AML, it seemed reasonable to include refractory patients
in this analysis since they also have a poor prognosis in the
majority of cohorts (19,22).
Several regimens of conventional chemotherapy have
been studied for r/rAML over the last few decades,
encompassing high-dose cytarabine in combination with
etoposide, purine analogs, mitoxantrone, or anthracyclines,
Figure 1 - Overall survival curve for the total cohort (n=60).
Table 2 - Comparison of baseline characteristics between the two groups.
MEC (n=28) FLAG-IDA (n=32) p
Age (median) 46 45.5 0.432
Sex Female (57%) Female (47%) 0.427
WBC (109/L) (median) 15.7 28.3 0.366
KPC colonization (%) 50 68.4 0.466
Genetic risk (%) 0.691
FLT3 status (%) (missing=3, 5%) 0.689
Previous induction 0.775
Indication for salvage treatment Refractory - 28.5% Refractory - 56.2% 0.029
Early relapsed (o1 y) - 53.5% Early relapsed (o1 y) - 37.5%
Late relapsed (X1 y) - 18% Late relapsed (X1 y) - 6.3%
Allo-SCT procedure 8/28 (28.5%) 9/32(28.1%) 0.470
4
Salvage regimens for r/rAML
da Silva WF et al.
CLINICS 2020;75:e1566
with variable responses reported (6,23-25). The CR rate
reported in our study is similar to that reported for most
regimens in r/rAML, especially in retrospective cohorts (23).
Several phase II trials testing the feasibility and safety of
salvage combinations have been conducted in recent years,
many of which did not report any remarkable results (CR
ranging from 12% to 89%) (6). It is important to mention that
this type of study may be limited by biased selection since a
fraction of r/rAML patients are not eligible for intensive
chemotherapy according to the formal criteria (23). A notice-
able early mortality rate was found in the current study, higher
than that reported in previous studies on MEC or FLAG-IDA
(4%–12%) (6,15,26-30). A recent study using mitoxantrone in
combination with FLAG showed an outstanding CR rate of
73%, raising issues on the choice of anthracycline for r/rAML
treatment (29). Greater treatment-related toxicity has already
been reported in patients with acute leukemia in Latin
America, even though no previous study has addressed this
subgroup of adult patients with refractory or relapsed
disease in Latin America (5,31-34).
By comparing the CR and survival endpoints between MEC
and FLAG-IDA, no remarkable difference was noticed in CR
and EFS, with only the FLT3-ITD status and execution of SCT
remaining as significant factors for survival in our cohort.
The former is an important marker of dismal prognosis in
AML, even when combined with NPM1 mutation (19).
Although FLT3 mutation was not screened at relapse in our
cohort, in most patients with an FLT3-ITD mutation at
diagnosis, the mutation is retained at relapse, with a higher
allelic burden at relapse than at diagnosis (35). This finding
reflects the clonal nature of AML and the progressively acquired
resistance to conventional chemotherapy in this setting. FLT3-
ITDmutation was also strongly correlated with survival in other
studies on r/rAML, and has been increasingly incorporated into
prognostic scores (8,36-38). The current development of FLT3
inhibitors will probably change this scenario since they have
already proven their clinical activity in the relapsed or refractory
setting, as well as in the first-line setting (18).
Schlenk et al. (38) evaluated prognostic baseline features in
1307 adult relapsed AML patients enrolled on prospective
trials of the German-Austrian AML Study Group (AMLSG)
between 1993 and 2009. In this study, the duration of the first
CR, allogeneic SCT during first-line therapy, age, and FLT3-
ITD were reported as unfavorable factors for survival, whereas
higher duration of the first CR, biallelic CEBPA mutation,
core binding factor AML, and allogeneic HCT as treatment of
relapse were favorable parameters for survival after relapse
(38). Previous studies have also emphasized the role of cyto-
genetics and CR duration for long-term survival in r/rAML
patients (39).
Figure 2 - Comparison of overall survival curves according to regimens (top left), age (top right), SCT execution (bottom left), and FLT3
status (bottom right).
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Previous attempts at finding differences among salvage
regimens for r/rAML have mostly failed, especially when
only conventional chemotherapy is used (6,7,23,24). A recent
retrospective publication by AMLSG involving 1025 AML
patients with induction failure showed an improved CR rate
in patients who received a salvage containing gemtuzumab
ozogamicin (odds ratio=0.75, po0.0001) (8). Other innova-
tive approaches for r/rAML include CPX-351, isocitrate
dehydrogenase inhibitors, venetoclax, and hypomethylating
agents, even though established approaches and combina-
tions are still not accurately defined (23,24).
’ CONCLUSIONS
In this analysis, there was no difference in outcome accor-
ding to the salvage regimen for AML, even though a slightly
higher refractoriness rate could be seen in the FLAG-IDA
arm. Furthermore, high early toxicity was found, emphasiz-
ing the role of supportive care and judicious selection of
patients for intensive salvage therapy in this setting. FLT3-
ITD mutation and SCT remained as significant factors for
survival in our study, which is in line with previous studies.
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’ APPENDIX
Supplementary Table - Comparison of baseline characteristics between the two groups in the post-matched cohort.
MEC (n=22) FLAG-IDA (n=22) p
Age (median) 46.5 43 0.264
WBC (x109/L) (median) 46.4 15.7 0.146
FLT3 status (%) 9 18 0.689
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